Melanoma Image Analysis Algorithm (MIAA) Validation Study
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02612168 |
Recruitment Status
:
Recruiting
First Posted
: November 23, 2015
Last Update Posted
: October 4, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Malignant Melanoma | Device: Melanoma Image Analysis Algorithm (MIAA) | Not Applicable |
Skin Analytics Limited have developed an algorithm (MIAA) which reviews photographs of pigmented lesions to determine whether melanoma is likely to be present. This study aims to establish how well MIAA determines the presence or absence of melanoma, compared to a biopsy.
Pigmented lesions that a dermatologist has decided to biopsy, and are suitable for photographing, will be photographed up to five times in a single visit. Three different camera will be used, and two different dermoscopic lens attachments will be used on smartphone cameras. Images will be analysed by MIAA and the results compared to the biopsy result. Clinicians, patients and the statistical analysis team will be blinded to the result of MIAA.
At least 65 pigmented lesions positive for melanoma (as determined by biopsy) are required, which is predicted to mean 1250 patients will be recruited.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 1250 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | Effectiveness of an Image Analysing Algorithm to Diagnose Melanoma Compared to Gold Standard Histological Determination |
Actual Study Start Date : | January 11, 2017 |
Estimated Primary Completion Date : | June 1, 2018 |
Estimated Study Completion Date : | June 14, 2018 |

Arm | Intervention/treatment |
---|---|
Experimental: All patients
Each patient will have any pigmented lesions (PLs) which are due to be biopsied, two PLs not due for biopsy and one patch of healthy skin photographed. Each will be photographed using three cameras: A standard DSLR and two smartphones with a dermoscopic lens attachment. Photographic images will be analysed by Melanoma Image Analysis Algorithm (MIAA)
|
Device: Melanoma Image Analysis Algorithm (MIAA)
The images will be analysed by MIAA (Melanoma Image Analysis Algorithm). The MIAA result for PLs that are biopsied will be compared to the diagnosis made from the biopsy. The MIAA result for PLs not biopsied will be compared to clinician diagnosis.
|
- The Area Under the Curve of a Receiver Operating Characteristic (AUROC) curve of MIAA result, using a maximum likelihood estimation (MLE) from all of the available images of biopsied lesions, compared to the biopsy result [ Time Frame: Study completion, on average 2 weeks ]Compare the MIAA result with the biopsy result
- The sensitivity of MIAA, using a MLE from all of the available images of biopsied lesions, compared to the biopsy result [ Time Frame: Study completion, on average 2 weeks ]%true positives, as determined by biopsy, identified
- The sensitivity of MIAA, using a MLE from all of the available images of non-biopsied lesions, compared to clinical assessment [ Time Frame: Study completion, on average 2 weeks ]%true positives, as determined by clinician, identified
- The specificity of MIAA, using a MLE from all of the available images of biopsied lesions, compared to the biopsy result [ Time Frame: Study completion, on average 2 weeks ]%true negatives, as determined by biopsy, identified
- The specificity of MIAA, using a MLE from all of the available images of non-biopsied lesions, compared to clinical assessment [ Time Frame: Study completion, on average 2 weeks ]%true negatives, as determined by clinician, identified
- The positive predictive value of MIAA, using a MLE from all of the available images of biopsied lesions, compared to the biopsy result [ Time Frame: Study completion, on average 2 weeks ]Probability that subjects with a positive MIAA result have a positive biopsy result
- The positive predictive value of MIAA, using a MLE from all of the available images of non-biopsied lesions, compared to clinical assessment [ Time Frame: Study completion, on average 2 weeks ]Probability that subjects with a positive MIAA result are thought likely to have melanoma by the clinician
- The negative predictive value of MIAA, using a MLE from all of the available images of biopsied lesions, compared to the biopsy result [ Time Frame: Study completion, on average 2 weeks ]Probability that subjects with a negative MIAA result have a negative biopsy result
- The negative predictive value of MIAA, using a MLE from all of the available images of non-biopsied lesions, compared to clinical assessment [ Time Frame: Study completion, on average 2 weeks ]Probability that subjects with a negative MIAA result are not thought likely to have melanoma by the clinician
- The false positive rate of MIAA, using a MLE from all of the available images of biopsied lesions, compared to the biopsy result [ Time Frame: Study completion, on average 2 weeks ]Probability that subject with positive MIAA result has a negative biopsy result
- The false positive rate of MIAA, using a MLE from all of the available images of non-biopsied lesions, compared to clinical assesment [ Time Frame: Study completion, on average 2 weeks ]Probability that subject with positive MIAA result are not thought likely to have melanoma by the clinician
- The false negative rate of MIAA, using a MLE from all of the available images of biopsied lesions, compared to the biopsy result [ Time Frame: Study completion, on average 2 weeks ]Probability that subject with negative MIAA result has a positive biopsy result
- The false negative rate of MIAA, using a MLE from all of the available images of non-biopsied lesions, compared to clinical assessment [ Time Frame: Study completion, on average 2 weeks ]Probability that subject with negative MIAA result are thought likely to have melanoma by the clinician
- The AUROC of MIAA, using images of biopsied lesions from each of the image capture apparatus combinations, compared to the biopsy result [ Time Frame: Study completion, on average 2 weeks ]Comparing the MIAA result, using images taken by each device, with the biopsy result
- The AUROC of MIAA, using images of non-biopsied lesions from each of the image capture apparatus combinations, compared to clinical assessment [ Time Frame: Study completion, on average 2 weeks ]Comparing the MIAA result, using images taken by each device, with the clinician's diagnosis
- The sensitivity of MIAA, using images of biopsied lesions from each of the image capture apparatus, compared to the biopsy result [ Time Frame: Study completion, on average 2 weeks ]%true positives, as determined by biopsy, identified by each imaging device
- The sensitivity of MIAA, using images of non-biopsied lesions from each of the image capture apparatus, compared to clinical assessment [ Time Frame: Study completion, on average 2 weeks ]%true positives, as determined by clinician, identified by each imaging device
- The specificity of MIAA, using images of biopsied lesions from each of the image capture apparatus, compared to the biopsy result [ Time Frame: Study completion, on average 2 weeks ]%true negatives, as determined by biopsy, identified by each imaging device
- The specificity of MIAA, using images of non-biopsied lesions from each of the image capture apparatus, compared to clinical assessment [ Time Frame: Study completion, on average 2 weeks ]%true negatives, as determined by clinician, identified by each imaging device
- The positive predictive value of MIAA, using images of biopsied lesions from each of the image capture apparatus, compared to the biopsy result [ Time Frame: Study completion, on average 2 weeks ]Probability that subjects with a positive MIAA result, using images taken by each device, have a positive biopsy result
- The positive predictive value of MIAA, using images of non-biopsied lesions from each of the image capture apparatus, compared to clinical assessment [ Time Frame: Study completion, on average 2 weeks ]Probability that subjects with a positive MIAA result, using images taken by each device, are thought likely to have melanoma by the clinician
- The negative predictive value of MIAA, using images of biopsied lesions from each of the image capture apparatus, compared to the biopsy result [ Time Frame: Study completion, on average 2 weeks ]Probability that subjects with a negative MIAA result, using images taken by each device, have a negative biopsy result
- The negative predictive value of MIAA, using images of non-biopsied lesions from each of the image capture apparatus, compared to clinical assessment [ Time Frame: Study completion, on average 2 weeks ]Probability that subjects with a negative MIAA result, using images taken by each device, are not thought likely to have melanoma by the clinician
- The false positive rate of MIAA, using images of biopsied lesions from each of the image capture apparatus, compared to the biopsy result [ Time Frame: Study completion, on average 2 weeks ]Probability that subject with positive MIAA result, using images taken by each device, has a negative biopsy result
- The false positive rate of MIAA, using images of non-biopsied lesions from each of the image capture apparatus, compared to clinical assessment [ Time Frame: Study completion, on average 2 weeks ]Probability that subject with positive MIAA result, using images taken by each device, are not thought likely to have melanoma by the clinician
- The false negative rate of MIAA, using images of biopsied lesions from each of the image capture apparatus, compared to the biopsy result [ Time Frame: Study completion, on average 2 weeks ]Probability that subject with negative MIAA result, using images taken by each device, has a positive biopsy result
- The false negative rate of MIAA, using images of non-biopsied lesions from each of the image capture apparatus, compared to clinical assessment [ Time Frame: Study completion, on average 2 weeks ]Probability that subject with negative MIAA result, using images taken by each device, are thought likely to have melanoma by the clinician
- The concordance of MIAA result between each of the image capture apparatus [ Time Frame: Study completion, on average 2 weeks ]The extent to which the image capture apparatus generate the same MIAA results as the other devices
- The number of adverse events, including adverse device events and serious adverse events. [ Time Frame: Study completion, on average 2 weeks ]The number of adverse events, including adverse device events and serious adverse events.
- The proportion of lesions with 4 images that can be analysed by MIAA [ Time Frame: Study completion, on average 2 weeks ]The proportion of lesions with 4 images that can be analysed by MIAA
- The proportion of lesions with at least 1 readable images that can be analysed by MIAA, [ Time Frame: Study completion, on average 2 weeks ]The proportion of lesions with at least 1 readable images that can be analysed by MIAA,
- The AUROC curve of the MIAA result, using MLE from all of the available images of non-biopsied PLs, compared to the clinical assessment [ Time Frame: Study completion, on average 2 weeks ]Compare the MIAA result with the clinicians assessment
- Impact of patient characteristics on the AUROC assessment of MIAA [ Time Frame: Study completion, on average 2 weeks ]A statistical model will test the whether patient characteristics, such as age, gender, and skin type, affect the overall result and if so by how much
- Impact of the image variables on the AUROC assessment of MIAA [ Time Frame: Study completion, on average 2 weeks ]A statistical model will test the whether image variables, such as manufacturer and lens type, affect the overall result and if so by how much
- Impact of the assessing clinician's level of experience on the AUROC assessment of MIAA [ Time Frame: Study completion, on average 2 weeks ]A statistical model will test the whether the clinicians' level of experience affect the overall result and if so by how much
- The concordance between the referring clinician's level of confidence for biopsy and the MIAA result [ Time Frame: Study completion, on average 2 weeks ]The extent to which the clinician's assessment of melanoma is the same as biopsy and MIAA results

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Participant is willing and able to give informed consent for participation in the study,
- Male or Female, aged 18 years or above,
- Have at least 1 lesion suitable for photographing that is scheduled for biopsy to determine the presence of melanoma,
- In the Investigators opinion, able and willing to comply with all study requirements.
Exclusion Criteria:
• Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02612168
Contact: Helen C Marsden, PhD | +44 7971571995 | helen@hi-ve.co.uk | |
Contact: Neil Daly | +44 7748 673187 | neil@skinanalytics.co.uk |
United Kingdom | |
Royal Devon and Exeter | Recruiting |
Exeter, Devon, United Kingdom, EX2 5DW | |
Contact: Rob James | |
Royal Stoke University Hospital | Recruiting |
Stoke, Staffordshire, United Kingdom, ST4 6QG | |
Contact: Amanda Hall | |
Contact: Emma Sadler | |
Royal Free London NHS Foundation Trust | Not yet recruiting |
London, United Kingdom, NW3 2QG | |
Contact: Ioulios Palamaras, MD PhD 02083752585 ioulios.palamaras@nhs.net |
Principal Investigator: | Ioulios Palamaras, MD PhD | Royal Free London NHS Foundation Trust |
Responsible Party: | Skin Analytics Limited |
ClinicalTrials.gov Identifier: | NCT02612168 History of Changes |
Other Study ID Numbers: |
SA-001-4ev |
First Posted: | November 23, 2015 Key Record Dates |
Last Update Posted: | October 4, 2017 |
Last Verified: | April 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No | |
Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Skin Analytics Limited:
Diagnosis skin imaging |
Additional relevant MeSH terms:
Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal |
Neoplasms by Histologic Type Neoplasms Neoplasms, Nerve Tissue Nevi and Melanomas |